UK’s NICE endorses Gleevec and Tasigna—but not Sprycel—for CML: http://www.bloomberg.com/news/2012-04-24/two-novartis-drugs-win-backing-in-final-u-k-leukemia-guidance.html In 2010, NICE rejected Tasigna, but NVS evidently gave them a better deal this time, as suggested in #msg-46517806.